Company · founded 1969

Leidos (United States)

Reston, United States · leidos.com

Manage this page

Citations, last 5 years: 6 675
Works, last 5 years: 1 109
h-index: 290
Scientists listed: 163
Grants since 2016: 653

Grants received

2018–2023 · contract · N02

Cell-based Immunotherapy Products

Gautam Mitra · Leidos (United States) · funded by National Institutes of Health

$6.6M

2018–2020 · contract · N02

IGF::OT::IGF STEVEN YOUNG CONSULTING MEDICINAL CHEMISTRY CONSULTANT SUPPORT

Steven Young · Leidos (United States) · funded by National Institutes of Health

$40k

2018–2023 · contract · N02

NCI OD-Frederick; 125073 Bldg. 560, Roof Exhaust Stacks; 9/24/2018 - 3/18/2022

Shannon Jackson · Leidos (United States) · funded by National Institutes of Health

$3.3M

2018–2028 · contract · N02

Development of an Integrated Canine Data Commons (ICDC)

John Otridge · Leidos (United States) · funded by National Institutes of Health

$3.5M

2018–2023 · contract · N01

Antibody Production and Characterization

William Bocik · Leidos (United States) · funded by National Institutes of Health

$1.1M

2018–2019 · contract · N02

IGF::OT::IGF STEVEN YOUNG CONSULTING MEDICINAL CHEMISTRY CONSULTANT SUPPORT

Steven Young · Leidos (United States) · funded by National Institutes of Health

$35.6k

2018–2028 · contract · N01

LEIDOS FUNDING TO59, OPTION 4 SUPPORT RESEARCH LAB AND BIOREPOSITORY IN LIBERIA

Calvin Proffitt · Leidos (United States) · funded by National Institutes of Health

$10.9M

2018–2023 · contract · N01

Rare and Recalcitrant Cancers for Establishing the Predictive Power of Patient-Derived Xenografts (PDXs)

Connie Suders · Leidos (United States) · funded by National Institutes of Health

$19.8M

2018–2028 · contract · N01

LEIDOS FUNDING TO59, OPTION 1 ONE ADDITIONAL SITE IN THE DRC

Calvin Proffitt · Leidos (United States) · funded by National Institutes of Health

$8.5M

2018–2024 · contract · N01

NCI-DCEG; Automated evaluation of biomarker-stained slides;

Mary Olanich · Leidos (United States) · funded by National Institutes of Health

$25.6kCervical Cancer and HPV Research

2018–2021 · contract · N01

Refractory Cancers Biospecimen Acquisition and Genomic Characterization

Jasmin Bavarva · Leidos (United States) · funded by National Institutes of Health

$4M

2018–2023 · contract · N01

Antibody Production and Characterization

William Bocik · Leidos (United States) · funded by National Institutes of Health

$4.3M

2018–2025 · contract · N02

Refractory Cancers Biospecimen Acquisition and Genomic Characterization

Jasmin Bavarva · Leidos (United States) · funded by National Institutes of Health

$258.6k

2018–2023 · contract · N01

PDX Panels from Common Tumors

Connie Suders · Leidos (United States) · funded by National Institutes of Health

$41.2M

2018–2023 · contract · N01

The Cancer Imaging Archive (TCIA) Clinical Trial Data Expansion;

John Freymann · Leidos (United States) · funded by National Institutes of Health

$5.3M

2018–2023 · contract · N01

HHSN261201500003I; HHSN26100069; 400.012.0069.0001; NCI CCG; Appropriated; Master Trial in Lymphoma (MasterLymph), Moonshot; 09/28/2018-09/27/2023

Daniel Soppet · Leidos (United States) · funded by National Institutes of Health

$1.4M

2018–2023 · contract · N01

Ebola Virus and Other Infectious Diseases in DRC and other Countries in Africa (Infrastructure and Capacity)

Beth Baseler · Leidos (United States) · funded by National Institutes of Health

$13M

2018–2023 · contract · N01

Ebola Virus and Other Infectious Diseases in DRC and other Countries in Africa (PREVAC and/or PREVAC like initiative)

Beth Baseler · Leidos (United States) · funded by National Institutes of Health

$22.5M

2018–2023 · contract · N01

Evaluation of Fever/Rash for Zika, Chikungunya, and Dengue virus in Mexico

Louis Grue · Leidos (United States) · funded by National Institutes of Health

$2.4M

2018–2023 · contract · N01

Cell-based Immunotherapy Products

Gautam Mitra · Leidos (United States) · funded by National Institutes of Health

$33.3M

2018–2027 · contract · N02

PDX Panels from Common Tumors

Connie Suders · Leidos (United States) · funded by National Institutes of Health

$26.7M

2018–2021 · contract · N01

Multi-omics Analyses and Integration of NCI-CPTAC-relevant Cancer Sample

William Bocik · Leidos (United States) · funded by National Institutes of Health

$3M

2018–2023 · contract · N01

NCI CBIIT;EXPAND DATA COMMONS

Dwayne Forquer · Leidos (United States) · funded by National Institutes of Health

$9.3M

2018–2019 · contract · N02

IGF::OT::IGF STEVEN YOUNG CONSULTING MEDICINAL CHEMISTRY CONSULTANT SUPPORT

Steven Young · Leidos (United States) · funded by National Institutes of Health

$26k

2018–2029 · contract · N02

Cell-based Immunotherapy Products

Gautam Mitra · Leidos (United States) · funded by National Institutes of Health

$13.6M

2018–2022 · contract · N01

Multi-omics Analyses and Integration of NCI-CPTAC-relevant Cancer Sample

William Bocik · Leidos (United States) · funded by National Institutes of Health

$36.5k

2018–2023 · contract · N01

Underlying Pharmacology of Brain Tumor Drug Treatment Response and Failure

Phd Parchment · Leidos (United States) · funded by National Institutes of Health

$5.4M

2018–2020 · contract · N01

HHSN261201500003I; HHSN26100081; 400.001.0081.0001; NCI-0D-Frederick; Appropriated; 125218 Bldg. 560, Building Generator/ATS; 09/18/2018 09/25/2020

Leaman Adam · Leidos (United States) · funded by National Institutes of Health

$2M

2018–2020 · contract · N01

Development of an Integrated Canine Data Commons (ICDC)

John Otridge · Leidos (United States) · funded by National Institutes of Health

$2M

2018–2023 · contract · N01

NCI-DCEG; Automated evaluation of biomarker-stained slides;

Mary Olanich · Leidos (United States) · funded by National Institutes of Health

$434kCervical Cancer and HPV Research

2018–2023 · contract · N01

Minimal Residual Disease Testing in a Clinical Trial for Acute Leukemia

Geoffrey Seidel · Leidos (United States) · funded by National Institutes of Health

$3.1M

2018–2023 · contract · N01

HHSN261201500003I; HHSN26100070; 400.020.0070.0001; NCI-DCEG; Appropriated; Automated evaluation of biomarker-stained slides; 09/24/2018-09/23/2023

Mary Olanich · Leidos (United States) · funded by National Institutes of Health

$500k

2018–2023 · contract · N01

Anti-HIV Broadly Neutralizing Monoclonal Antibody (bnAbs) Drug Substance (DS) Clinical Trial Material Production and Release

David Lindsay · Leidos (United States) · funded by National Institutes of Health

$5.9M

2018–2022 · contract · N01

HIV and Tumor Molecular Characterization Project (HTMCP)

Maureen Dyer · Leidos (United States) · funded by National Institutes of Health

$1.5M

2018–2023 · contract · N01

NCI-DCEG; Appropriated; Automated evaluation of biomarker-stained slides; 09/24/2018-09/23/2023

Mary Olanich · Leidos (United States) · funded by National Institutes of Health

$344.8k

2018–2023 · contract · N01

NCI CBIIT;EXPAND DATA COMMONS

Dwayne Forquer · Leidos (United States) · funded by National Institutes of Health

$9.6M

2018–2026 · contract · N02

NCI OD-Frederick; 125073 Bldg. 560, Roof Exhaust Stacks; 9/24/2018 - 3/18/2022

Shannon Jackson · Leidos (United States) · funded by National Institutes of Health

$3M

2018–2021 · contract · N01

Medicinal Chemistry Support for Chemopreventive Agent Development

Ligia Pinto · Leidos (United States) · funded by National Institutes of Health

$1.1M

2018–2023 · contract · N01

Anti-HIV Broadly Neutralizing Monoclonal Antibody (bnAbs) Drug Substance (DS) Clinical Trial Material Production and Release

David Lindsay · Leidos (United States) · funded by National Institutes of Health

$7M

2018–2025 · contract · N02

Refractory Cancers Biospecimen Acquisition and Genomic Characterization

Jasmin Bavarva · Leidos (United States) · funded by National Institutes of Health

$40.3k